Microsure is a technology company.
Microsure specializes in robotic microsurgery, enabling surgeons to perform complex procedures on the smallest anatomical structures with enhanced precision and comfort.
Microsure has raised $41.0M across 1 funding round.
Microsure has raised $41.0M in total across 1 funding round.
Microsure is a Dutch MedTech company developing robotic systems for microsurgery, with its flagship product MUSA, the world's first clinically available CE-certified surgical robot for open microsurgery.[1][3][5] Headquartered in Son en Breugel near Eindhoven, it serves microsurgeons performing procedures like lymphaticovenular anastomosis (LVA), free flap surgery, and nerve repair, addressing human limitations in precision on sub-millimeter anatomical structures such as tiny blood vessels, lymph vessels, and nerves.[3][4][5] By providing tremor-filtered, scaled joystick control and compatibility with surgeons' preferred instruments, MUSA enables superhuman precision, expanded dexterity, and ergonomic operation, solving challenges like surgeon fatigue and scarcity of supermicrosurgery expertise to ensure no patient needing such procedures goes untreated.[3][4][5] The company shows strong growth momentum, with 28 employees, recent funding including an Innovation Loan from the Dutch Ministry of Economic Affairs and asset financing from Kineo, advancing MUSA-3 toward clinical studies, FDA clearance, and expanded CE-mark certification.[2][3]
Microsure was founded in 2016 by Eindhoven University of Technology and Maastricht University Medical Center, emerging from collaborative research to overcome human boundaries in supermicrosurgery.[2][3] The idea stemmed from recognizing that even elite microsurgeons struggle with maintaining focus and precision on the smallest structures, limiting access to life-improving procedures like reconstructive surgeries.[4][5] Early traction came through close cooperation with microsurgeons and engineers to develop MUSA, starting with MUSA-2, which demonstrated promising clinical results and led to CE certification as the first such robot.[1][2][5] Under CEO Sjaak Deckers, the company has evolved, leveraging partnerships like Jama Software for development and expanding its clinical network for pivotal FDA pursuits.[1][2]
Microsure rides the wave of robotic surgery expansion beyond general procedures into niche microsurgery, where precision demands exceed human capability amid rising needs for reconstructive treatments post-cancer, trauma, or lymphedema.[4][5] Timing aligns with maturing MedTech regulations—evidenced by its CE mark and FDA trajectory—and global surgeon shortages, amplified by aging populations increasing microvascular demands.[2][5] Favorable market forces include Dutch innovation funding, university-tech synergies, and hospital financing models enabling adoption.[2] By democratizing supermicrosurgery, Microsure influences the ecosystem, potentially standardizing robot-assisted precision in plastics, reconstructive, and hand surgery, boosting outcomes and accessibility as praised by international experts.[5]
Microsure is poised to commercialize MUSA-3 post-clinical trials, targeting FDA clearance to penetrate U.S. markets and scale globally via expanded leasing and partnerships.[2][5] Trends like AI-enhanced imaging, hybrid OR integrations, and personalized MedTech will amplify its trajectory, while regulatory wins could spur acquisitions by majors like Intuitive Surgical. Its influence may evolve from pioneer to ecosystem enabler, training more surgeons and redefining microsurgery standards—ultimately fulfilling the vision of treating every eligible patient.[4][5] This positions Microsure as a high-momentum bet in precision MedTech, transforming lives one vessel at a time.
Microsure has raised $41.0M in total across 1 funding round.
Microsure's investors include Coparion.
Microsure has raised $41.0M across 1 funding round. Most recently, it raised $41.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $41.0M Series B | Coparion |